New pill aims to tackle high blood pressure and weight together

NCT ID NCT07360275

Not yet recruiting Disease control Sponsor: Vincentage Pharma Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called VCT220 in 160 adults with high blood pressure who are also overweight or obese. Participants will take either VCT220 or a placebo pill for 20 weeks. The main goal is to see if VCT220 can safely lower blood pressure more than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VCT220 tablet
What this could lead to: If successful, this could point toward a new treatment option for people with high blood pressure who are also overweight or obese.
What could go wrong: This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

Beijing Luhe Hospital

Beijing, Beijing Municipality, 100044, China
Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.